BioCryst Pharmaceuticals : Second Quarter 2022 Conference Call
August 04, 2022 at 05:43 pm EDT
Share
Second Quarter 2022 Results Call
Corporate Update & Financial Results
August 4, 2022
Forward-Looking Statements
BioCryst's presentation may contain forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information and company performance or achievements. These statements are subject to known and unknown risks and uncertainties which may cause our actual results, performance or achievements to be materially different from any future results or performances expressed or implied in this presentation. You should not place undue reliance on the forward-looking statements. For additional information, including important risk factors, please refer to BioCryst's documents filed with the SEC and located at https://ir.biocryst.com/financial-information/sec-filings.
2
Agenda
Corporate Update:
Jon Stonehouse - President and Chief Executive Officer
ORLADEYO® (berotralstat) Launch Update:
Charlie Gayer - Chief Commercial Officer
Financial Update
Anthony Doyle - Chief Financial Officer
BCX9930 Update
Dr. Helen Thackray - Chief Research and Development Officer
Summary and Q&A
3
Finance Summary
(figures in millions)
2Q22 Cash Position
Cash, cash equivalents, restricted cash & investments at June 30, 2021
$223
Cash, cash equivalents, restricted cash & investments at June 30, 2022
$419
Senior Credit Facility A
$151
Proforma cash, cash equivalents, restricted cash & investments at June 30, 2022 B
$492 C
Proforma Senior Credit Facility B
$226
- From Athyrium Capital Management, term loan of $125M interest-only for 5-year term, $25.8 in interest payment-in-kind (PIK) has been added to principal since issuance
- On July 29, 2022 the Company completed the delayed draw of $75M under term loan B and C with Athyrium Capital Management.
- Approximately
2022 FY Guidance
ORLADEYO Revenue
$255 - $265
Operating Expenses (excluding non-cash comp)
$390 - $400
4
Second Quarter 2022 Results Call
Corporate Update & Financial Results
August 4, 2022
Attachments
Original Link
Original Document
Permalink
Disclaimer
BioCryst Pharmaceuticals Inc. published this content on 04 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 August 2022 21:36:04 UTC.
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
BIOCRYST PHARMACEUTICALS, INC. 
